Eupraxia Pharmaceuticals Inc (EPRX) - Total Liabilities

Latest as of September 2025: CA$5.43 Million CAD ≈ $3.93 Million USD

Based on the latest financial reports, Eupraxia Pharmaceuticals Inc (EPRX) has total liabilities worth CA$5.43 Million CAD (≈ $3.93 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore EPRX cash flow conversion to assess how effectively this company generates cash.

Eupraxia Pharmaceuticals Inc - Total Liabilities Trend (2017–2024)

This chart illustrates how Eupraxia Pharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data. Check Eupraxia Pharmaceuticals Inc liquid asset ratio to evaluate the company's liquid asset resilience ratio.

Eupraxia Pharmaceuticals Inc Competitors by Total Liabilities

The table below lists competitors of Eupraxia Pharmaceuticals Inc ranked by their total liabilities.

Company	Country	Total Liabilities
Chieftek Precision Co Ltd TW:1597	Taiwan	NT$1.68 Billion
Lootom Telcovideo Network Wuxi Co Ltd SHE:300555	China	CN¥70.69 Million
Shanghai Rychen Technologies Co. Ltd. A SHE:301273	China	CN¥233.16 Million
JSL S.A SA:JSLG3	Brazil	R$10.62 Billion
BNY Mellon Strategic Municipals Inc NYSE:LEO	USA	$222.97 Million
Acacia Research Corporation NASDAQ:ACTG	USA	$192.03 Million
Ambac Financial Group Inc NYSE:AMBC	USA	$1.00 Billion
Xinjiang Tianshun Supply Chain Co Ltd SHE:002800	China	CN¥523.26 Million

Liability Composition Analysis (2017–2024)

This chart breaks down Eupraxia Pharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see EPRX stock market capitalisation.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	23.98	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.04	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.04	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Eupraxia Pharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Eupraxia Pharmaceuticals Inc (2017–2024)

The table below shows the annual total liabilities of Eupraxia Pharmaceuticals Inc from 2017 to 2024.

Year	Total Liabilities	Change
2024-12-31	CA$4.46 Million ≈ $3.23 Million	-82.53%
2023-12-31	CA$25.55 Million ≈ $18.48 Million	+76.03%
2022-12-31	CA$14.51 Million ≈ $10.50 Million	+24.36%
2021-12-31	CA$11.67 Million ≈ $8.44 Million	-49.52%
2020-12-31	CA$23.12 Million ≈ $16.72 Million	+7.94%
2019-12-31	CA$21.42 Million ≈ $15.49 Million	+49.30%
2018-12-31	CA$14.34 Million ≈ $10.38 Million	+1849.47%
2017-12-31	CA$735.82K ≈ $532.28K	--

About Eupraxia Pharmaceuticals Inc

TO:EPRX Canada Biotechnology

Market Cap

$393.86 Million

CA$544.47 Million CAD

Market Cap Rank

#13760 Global

#396 in Canada

Share Price

CA$10.75

Change (1 day)

+0.94%

52-Week Range

CA$5.16 - CA$12.50

All Time High

CA$12.50